Brief: Theranexus Announces Inclusion Of Last Patient In THN102 Phase II Trial
29/10/2018 06:44
Oct 29 (Reuters) - THERANEXUS SA ALTHX.PA :
* THERANEXUS ANNOUNCES INCLUSION OF LAST PATIENT IN PHASE II
TRIAL
OF DRUG CANDIDATE THN102 ON NARCOLEPSY PATIENTS
Source text for Eikon: ID:nACT55730
Further company coverage: ALTHX.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease